| 2026-05-20 |
详情>>
内部人交易：
TOBIN JAMES R等共交易7笔
|
| 2026-05-05 |
详情>>
股本变动：
变动后总股本3456.09万股
|
| 2026-05-05 |
详情>>
业绩披露：
2026年一季报每股收益0.21美元,归母净利润731.50万美元,同比去年增长-71.52%
|
| 2026-05-05 |
财报披露：
美东时间 2026-05-05 盘后发布财报
|
| 2026-04-10 |
股东大会：
将于2026-05-20召开股东大会
会议内容 ▼▲
- 1.To elect eight directors, each to serve until the 2027 Annual Meeting of Shareholders;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To approve an amendment to the TransMedics Group, Inc. Amended and Restated 2019 Stock Incentive Plan (the “2019 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2019 Plan by 2,750,000 shares and make certain other changes;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;
5.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2026-02-24 |
详情>>
业绩披露：
2025年年报每股收益5.60美元,归母净利润1.90亿美元,同比去年增长436.58%
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.50美元,归母净利润8490.80万美元,同比去年增长196.81%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益1.79美元,归母净利润6058.90万美元,同比去年增长148.41%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.76美元,归母净利润2568.20万美元,同比去年增长110.56%
|
| 2025-04-10 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect eight directors, each to serve until the 2026 Annual Meeting of Shareholders;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
4.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益1.07美元,归母净利润3546.40万美元,同比去年增长241.70%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.86美元,归母净利润2860.70万美元,同比去年增长198.44%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益0.74美元,归母净利润2439.10万美元,同比去年增长770.64%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益0.37美元,归母净利润1219.70万美元,同比去年增长562.71%
|
| 2024-04-10 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect eight (8) directors, each to serve until the 2025 annual meeting of shareholders;
2.To approve, on a non-binding advisory basis, the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;
4.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益-0.77美元,归母净利润-2502.8万美元,同比去年增长30.92%
|
| 2023-04-12 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect eight (8) directors, each to serve until the 2024 annual meeting of our shareholders;
2.To approve, on a non-binding advisory basis, the compensation paid to our named executive officers;
3.To approve an amendment to the TransMedics Group, Inc. 2019 Stock Incentive Plan (the “2019 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2019 Plan by 1,000,000 shares;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2022-04-20 |
股东大会：
将于2022-06-01召开股东大会
会议内容 ▼▲
- 1.To elect eight (8) directors, each to serve until the 2023 annual meeting of our shareholders;
2.To approve, on a non-binding advisory basis, the compensation paid to our named executive officers;
3.To approve, on a non-binding advisory basis, the frequency of future “say on pay” votes;
4.To approve an amendment to the TransMedics Group, Inc. 2019 Stock Incentive Plan (the “2019 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2019 Plan by 1,500,000 shares;
5.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
6.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2022-02-25 |
复牌提示：
2022-02-24 09:32:23 停牌，复牌日期 2022-02-24 09:32:23
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-16 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.To elect eight (8) directors, each to serve until the 2022 annual meeting of our shareholders;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
3.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|
| 2020-04-14 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors, each to serve until the 2021 annual meeting of our shareholders;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020; 3.To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.
|